Atomoxetine in autism spectrum disorder : no effects on <font color="blue">social_1</font> <font color="blue">functioning_1</font> <font color="blue">;_1</font> some beneficial effects on <font color="blue">stereotyped_1</font> <font color="blue">behaviors_1</font> <font color="blue">,_1</font> <font color="blue">inappropriate_1</font> <font color="blue">speech_1</font> <font color="blue">,_1</font> and <font color="blue">fear_1</font> <font color="blue">of_1</font> <font color="blue">change_1</font> <font color="blue">._1</font> 
<br>
<br> UNLABELLED Abstract Objective : The objective of this study was to investigate the short - term treatment effects of atomoxetine on <font color="blue">autism_1</font> <font color="blue">spectrum_1</font> <font color="blue">disorder_1</font> <font color="blue">(_1</font> <font color="blue">ASD_1</font> <font color="blue">)_1</font> <font color="blue">symptoms_1</font> in children and adolescents with both ASD and attention - deficit / hyperactivity disorder ( ADHD ) . 
<br> METHODS A total of 97 patients 6 - 17 years of age , with ASD and ADHD , were treated with 1.2 â€‰ mg / kg / day of atomoxetine during an 8 week double - blind placebo - controlled period . Here , we investigated effects on two <font color="blue">parent_1</font> <font color="blue">-_1</font> <font color="blue">based_1</font> <font color="blue">secondary_1</font> <font color="blue">outcome_1</font> <font color="blue">measures_1</font> <font color="blue">,_1</font> <font color="blue">the_1</font> <font color="blue">Aberrant_1</font> <font color="blue">Behavior_1</font> <font color="blue">Checklist_1</font> <font color="blue">(_1</font> <font color="blue">ABC_1</font> <font color="blue">)_1</font> <font color="blue">and_1</font> <font color="blue">the_1</font> <font color="blue">Children_1</font> <font color="blue">'s_1</font> <font color="blue">Social_1</font> <font color="blue">Behavior_1</font> <font color="blue">Questionnaire_1</font> <font color="blue">(_1</font> <font color="blue">CSBQ_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> 
<br> RESULTS After 8 weeks of double - blind treatment , atomoxetine administration was associated with significant treatment effects on the <font color="blue">ABC_1</font> <font color="blue">subscales_1</font> <font color="blue">Hyperactivity_1</font> <font color="blue">,_1</font> <font color="blue">Inappropriate_1</font> <font color="blue">Speech_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">Stereotypic_1</font> <font color="blue">Behavior_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">on_1</font> <font color="blue">the_1</font> <font color="blue">CSBQ_1</font> <font color="blue">subscale_1</font> <font color="blue">Fear_1</font> <font color="blue">for_1</font> <font color="blue">Changes_1</font> <font color="blue">._1</font> 
<br> CONCLUSIONS Our study results indicate no beneficial effects of atomoxetine on <font color="blue">social_1</font> <font color="blue">functioning_1</font> <font color="blue">._1</font> However , atomoxetine may ameliorate <font color="blue">restricted_1</font> <font color="blue">and_1</font> <font color="blue">stereotyped_1</font> <font color="blue">behaviors_1</font> <font color="blue">and_1</font> <font color="blue">communication_1</font> <font color="blue">._1</font> This study has been registered in ClinicalTrials.gov ( www.clinicaltrials.gov ) under registration number NCT00380692 .